Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates

Core Viewpoint - Immunome, Inc. reported a quarterly loss of $0.78 per share, which was worse than the Zacks Consensus Estimate of a loss of$0.60, marking a 30% earnings surprise [1][2] Financial Performance - The company posted revenues of $2.91 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 19.05$3.57 million year-over-year [2] - Over the last four quarters, Immunome has surpassed consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.63 on revenues of$5.11 million, and for the current fiscal year, it is -$4.18 on revenues of$7.65 million [7] Stock Performance - Immunome shares have increased by approximately 16.7% since the beginning of the year, compared to a 25.5% gain in the S&P 500 [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Industry Outlook - The Medical - Biomedical and Genetics industry is currently ranked in the top 26% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]